Related Experiment Video

Updated: Jul 18, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

The role of PET scanning in determining pharmacoselective doses in oncology drug development

P Price1

  • 1Academic Department of Radiation Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK. pat.price@manchester.ac.uk

Ernst Schering Research Foundation Workshop
|November 23, 2006
PubMed

Insights

Molecular imaging, particularly positron emission tomography (PET), enhances oncology drug development by measuring molecular pathways and drug effects in vivo. This technology accelerates clinical trials and identifies drug mechanisms, improving cancer treatment strategies.

Area of Science:

  • Oncology
  • Molecular Imaging
  • Radiochemistry

Background:

  • Molecular imaging offers sensitive and specific in vivo measurement of molecular pathways.
  • Its application in oncology has seen significant advancement in the past decade.

Purpose of the Study:

  • To highlight the role of molecular imaging, specifically PET, in modern oncology drug development.
  • To discuss the potential of PET in measuring drug pharmacokinetics, pharmacodynamics, and mechanisms of action.
  • To emphasize the growing importance of PET for noninvasive biomarkers in personalized medicine.

Main Methods:

  • Utilizing positron-emitting isotopes for molecular labeling.
  • Employing positron emission tomography (PET) cameras for radiation detection.
  • Measuring in vivo pharmacokinetics and pharmacodynamics of anti-cancer drugs.

Main Results:

  • PET enables in vivo measurement of anti-cancer drug pharmacokinetics and mechanisms of action.
  • Radiolabeled tracers facilitate assessment of pharmacodynamic endpoints and target engagement.
  • Integration of PET in early drug development reduces time to clinical trials and aids in mechanism identification.

Conclusions:

  • Molecular imaging, especially PET, is crucial for advancing oncology drug development.
  • PET facilitates personalized medicine through noninvasive biomarker assessment.
  • Further international collaboration between academia and industry is needed to prioritize PET technology development.

More Related Videos

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

Preclinical Positron Emission Tomography with Body Conforming Animal Molds for Cloud-Based Automated Image Analysis in Mice07:45

Preclinical Positron Emission Tomography with Body Conforming Animal Molds for Cloud-Based Automated Image Analysis in Mice

Published on: October 25, 2024

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).